Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)
Sponsor: Merck Sharp & Dohme LLC
This PHASE2 trial investigates Triple Negative Breast Neoplasms and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 33 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
33 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Jan 2026 — Mar 2026 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 28 earlier versions
-
Dec 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
Phase: PHASE2_PHASE3 → PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2_PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Augusta, United States , Avignon, France , Bad Nauheim, Germany , Barcelona, Spain , Barranquilla, Colombia , Besançon, France , Blackpool, United Kingdom , Bonn, Germany , Boston, United States and 95 more locations